Brief: Karuna Therapeutics Announces Global License Agreement
02/02/2023 12:09
Feb 2 (Reuters) - Karuna Therapeutics Inc KRTX.O :
* KARUNA THERAPEUTICS ANNOUNCES EXCLUSIVE GLOBAL LICENSE
AGREEMENT
FOR GOLDFINCH BIO’S INVESTIGATIONAL TRPC4/5 PRODUCT CANDIDATES
* KARUNA THERAPEUTICS INC - GOLDFINCH BIO ASSIGNMENT ESTATE
TO
RECEIVE $15 MILLION UPFRONT PAYMENT
* KARUNA THERAPEUTICS INC - TO SHARE DETAILS ON PLANNED
DEVELOPMENT OF GFB-887 FOR TREATMENT OF MOOD AND ANXIETY
DISORDERS IN SECOND HALF OF 2023
* KARUNA THERAPEUTICS INC - GOLDFINCH BIO ASSIGNMENT ESTATE
TO
RECEIVE UP TO $520 MILLION IN POTENTIAL MILESTONE PAYMENTS PLUS
ROYALTIES
* KARUNA THERAPEUTICS INC-CO TO OBTAIN EXCLUSIVE GLOBAL
LICENSE TO
DEVELOP, MANUFACTURE, COMMERCIALIZE MULTIPLE TRPC4/5 CANDIDATES
Source text for Eikon: ID:nBwblY115a
Further company coverage: KRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Karuna Therapeutics
See all newsMoody's says pharma outlook turns 'positive' on GLP-1 drug push
Brief: Karuna Therapeutics Says Complaint Was Filed By Karuna Stockholder Seeking To Enjoin Proposed Merger With Bristol-Myers Squibb
Karuna Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Karuna Therapeutics Inc expected to post a loss of $2.65 a share - Earnings Preview
Bristol Myers posts better-than-expected 4th-quarter results (updated)